These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 38466449)
1. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer. Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X Front Immunol; 2023; 14():1145552. PubMed ID: 36969219 [TBL] [Abstract][Full Text] [Related]
3. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer. Wang Z; Liu H; Gong Y; Cheng Y Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights. Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J Front Immunol; 2023; 14():1219652. PubMed ID: 37457713 [TBL] [Abstract][Full Text] [Related]
5. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment. Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507 [TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer. Yu Z; Zhu Y; Ji J Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486 [TBL] [Abstract][Full Text] [Related]
7. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer. Liu Y; He X; Yang YI J Biosci; 2024; 49():. PubMed ID: 38287674 [TBL] [Abstract][Full Text] [Related]
9. PANoptosis-related molecular clustering and prognostic signature associated with the immune landscape and therapy response in breast cancer. Cao Y; Guan L; Yang L; Wei C Medicine (Baltimore); 2024 Sep; 103(37):e39511. PubMed ID: 39287311 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H Front Immunol; 2023; 14():1213947. PubMed ID: 37965307 [TBL] [Abstract][Full Text] [Related]
11. Identification of a pyroptosis-related prognostic signature in breast cancer. Chen H; Luo H; Wang J; Li J; Jiang Y BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644 [TBL] [Abstract][Full Text] [Related]
12. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. Jiang M; Wu X; Bao S; Wang X; Qu F; Liu Q; Huang X; Li W; Tang J; Yin Y Front Immunol; 2022; 13():946468. PubMed ID: 35935965 [No Abstract] [Full Text] [Related]
13. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature. Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C Front Immunol; 2023; 14():1199465. PubMed ID: 37469520 [TBL] [Abstract][Full Text] [Related]
14. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model. Lv Y; Bai Z; Wang X; Liu J; Li Y; Zhang X; Shan Y Sci Rep; 2022 Nov; 12(1):20524. PubMed ID: 36443508 [TBL] [Abstract][Full Text] [Related]
16. Predictive Value of the Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH Front Immunol; 2021; 12():643282. PubMed ID: 34421886 [TBL] [Abstract][Full Text] [Related]
17. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer. Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733 [TBL] [Abstract][Full Text] [Related]
18. Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma. Ye Y; Luo Y; Guo T; Zhang C; Sun Y; Xu A; Ji L; Ou J; Wu SY Front Endocrinol (Lausanne); 2023; 14():1179050. PubMed ID: 37600707 [TBL] [Abstract][Full Text] [Related]
19. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G Front Genet; 2022; 13():919389. PubMed ID: 35783281 [No Abstract] [Full Text] [Related]
20. Construction of a prognostic model for breast cancer based on moonlighting genes. Zhang M; Zhang D; Wang Q; Lin G Hum Mol Genet; 2024 Jun; 33(12):1023-1035. PubMed ID: 38491801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]